<DOC>
	<DOCNO>NCT01716520</DOCNO>
	<brief_summary>The purpose study evaluate lung function response UMEC/VI , UMEC , VI individual patient use cross-over design . This multicenter , randomize , double-blind , 3-way crossover study . Eligible subject randomize sequence UMEC 62.5mcg , VI 25mcg , UMEC/VI 62.5/25mcg . All subject receive treatment once-daily 14 day , treatment separate 10-14 day washout period . There 5-7 day run-in period prior randomization .</brief_summary>
	<brief_title>Cross-Over Study Subjects With COPD , Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg , Vilanterol 25mcg , Umeclidinium/Vilanterol 62.5/25mcg</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Type Patient : Outpatient Informed Consent : A sign date write informed consent prior study participation Age : Subjects 40 year age old Visit 1 Gender : Male female subject . COPD diagnosis : As defined American Thoracic Society/European Respiratory Society ( ATS/ERS ) Severity disease : A pre postsalbutamol FEV1/FVC ratio &lt; 0.70 pre postsalbutamol FEV1 ≤ 70 % predict normal value Visit 1 Smoking History : Current former cigarette smoker history cigarette smoke ≥ 10 packyears Visit 1 Female subject non childbearing potential OR female subject child bear potential , negative pregnancy test screening , agree consistently correctly use one acceptable contraceptive method Pregnancy : Women pregnant lactate plan become pregnant study Asthma : A current diagnosis asthma Other Respiratory Disorders : Known alpha1 antitrypsin deficiency , active lung infection ( tuberculosis ) , lung cancer absolute exclusionary condition . Other Diseases/Abnormalities : Subjects historical current evidence clinically significant cardiovascular , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) hematological abnormality uncontrolled and/or previous history cancer remission &lt; 5 year prior Visit 1 Contraindications : A history allergy hypersensitivity anticholinergic/muscarinic receptor antagonist , beta2agonist , lactose/milk protein magnesium stearate medical condition narrowangle glaucoma , prostatic hypertrophy bladder neck obstruction , opinion study physician contraindicates study participation use inhale anticholinergic . Hospitalization : Hospitalization COPD pneumonia within 12 week prior Visit 1 . Lung Resection : Subjects lung volume reduction surgery within 12 month prior Visit 1 . 12Lead ECG : An abnormal significant ECG find 12lead ECG conduct Visit 1 Screening Labs : Significantly abnormal find clinical chemistry hematology test Visit 1 determine study investigator . Medication Prior Spirometry : Unable withhold salbutamol 4 hour period require prior spirometry test study visit spirometry test perform home . Medications Prior Screening : Use prohibit medication accord defined time interval prior Visit 1 Oxygen : Use longterm oxygen therapy ( LTOT ) describe oxygen therapy prescribe great 12 hour day . Asneeded oxygen use ( i.e. , ≤ 12 hour per day ) exclusionary . Nebulized Therapy : Regular use ( prescribe use every day , asneeded use ) shortacting bronchodilator ( e.g. , salbutamol , ipratropium bromide ) via nebulized therapy Pulmonary Rehabilitation Program : Participation acute phase pulmonary rehabilitation program within 4 week prior Visit 1 . Subjects maintenance phase pulmonary rehabilitation program exclude . Drug Alcohol Abuse : A know suspected history alcohol drug abuse within 2 year prior Visit 1 . Affiliation Investigator Site : Is investigator , subinvestigator , study coordinator , employee participate investigator study site , immediate family member aforementioned involve study . Inability read : In opinion Investigator , subject unable read and/or would able complete questionnaire</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>long-acting muscarinic antagonist</keyword>
	<keyword>long-acting beta-agonist</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>vilanterol</keyword>
	<keyword>umeclidinium</keyword>
</DOC>